NLRP3 and Insulin resistance: Inhibition of the NLRP3 inflammasome activation process and thus inhibition of proinflammatory cytokine release may serve as an early modulable target to improve the inflammatory cascade in patients with insulin resistance combined with ischemic cerebrovascular disease.